Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial

AIMS: The direct renin inhibitor, aliskiren, is known to reduce plasma renin activity (PRA), but whether the efficacy of aliskiren varies based on an individual’s baseline PRA in patients hospitalized for heart failure (HF) is presently unknown. We characterized the prognostic value of PRA and deter...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Heart Fail
Autors principals: Vaduganathan, Muthiah, Cheema, Baljash, Cleveland, Erin, Sankar, Kamya, Subacius, Haris, Fonarow, Gregg C., Solomon, Scott D., Lewis, Eldrin F., Greene, Stephen J., Maggioni, Aldo P., Böhm, Michael, Zannad, Faiez, Butler, Javed, Gheorghiade, Mihai
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676477/
https://ncbi.nlm.nih.gov/pubmed/29143416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.973
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars